A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS

OncoImmunology

Volumn 4, Issue 8, 2015, Pages

  Yoshitake, Yoshihiro ^a,b   Nishimura, Yasuharu ^a   Nakamura, Yusuke ^c,d   Shinohara, Masanori ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Itoh Dento Maxillofacial Hospital   (Japan)

^c THE UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

cancer vaccine therapy; cytotoxic T lymphocytes; head and neck squamous cell cancer; multiple peptides vaccine; phase II clinical trial; tumor associated antigens

Indexed keywords

COMPLEMENTARY DNA; PEPTIDE VACCINE; SYNTHETIC PEPTIDE; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84929703301     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1022307     Document Type: Article

References (10)

1. D.M.Brizel, R.Esclamado. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 2006; 24:2612-7; PMID:16763273; http://dx.doi.org/10.1200/JCO.2005.05.2829.
2. T.Suda, T.Tsunoda, Y.Daigo, Y.Nakamura, H.Tahara. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007; 98:1803-8; PMID:17784873; http://dx.doi.org/10.1111/j.1349-7006.2007.00603.x.
3. K.Kono, Y.Mizukami, Y.Daigo, A.Takano, K.Masuda, K.Yoshida, T.Tsunoda, Y.Kawaguchi, Y.Nakamura, H.Fujii. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100:1502-9; PMID:19459850; http://dx.doi.org/10.1111/j.1349-7006.2009.01200.x.
4. T.Yamabuki, Y.Daigo, T.Kato, S.Hayama, T.Tsunoda, M.Miyamoto, T.Ito, M.Fujita, M.Hosokawa, S.Kondo et al. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006; 28:1375-84; PMID:16685439; http://dx.doi.org/10.3892/ijo.28.6.1375
5. N.Ishikawa, A.Takano, W.Yasui, K.Inai, H.Nishimura, H.Ito, Y.Miyagi, H.Nakayama, M.Fujita, M.Hosokawa et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007; 67:11601-11; PMID:18089789; http://dx.doi.org/10.1158/0008-5472.CAN-07-3243.
6. K.Kono, H.Iinuma, Y.Akutsu, H.Tanaka, N.Hayashi, Y.Uchikado, T.Noguchi, H.Fujii, K.Okinaka, R.Fukushima et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10:141-9; PMID:22776426; http://dx.doi.org/10.1186/1479-5876-10-141.
7. Y.Yoshitake, D.Fukuma, A.Yuno, M.Hirayama, H.Nakayama, T.Tanaka, M.Nagata, Y.Takamune, K.Kawahara, Y.Nakagawa et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 2015; 21:312-21; PMID:25391695; http://dx.doi.org/10.1158/1078-0432.CCR-14-0202.
8. U.Keilholz, J.Weber, J.H.Finke, D.I.Gabrilovich, W.M.Kast, M.L.Disis, J.M.Kirkwood, C.Scheibenbogen, J.Schlom, V.C.Maino et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97-138; PMID:12074049; http://dx.doi.org/10.1097/00002371-200203000-00001.
9. + T-cell immunity in patients with malignant disease. OncoImmunol 2014; 3:e28100-1-15; PMID:25340007; http://dx.doi.org/10.4161/onci.28100.
10. + T-cell immunity in cancer patients. Int J Cancer 2014; 134:352-66; PMID:24734272; http://dx.doi.org/10.1002/ijc.28376.